QTRX — Quanterix Corporation

Quanterix Corporation (QTRX) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $40.2 million, a 12% increase year-over-year.
• Simoa Revenue: $23 million, a 36% organic decline.
• Spatial Revenue: $17.2 million, down 9% year-over-year.
• Gross Profit: $17.2 million with a gross margin of 42.8% (non-GAAP gross margin: 45.9%).
• Operating Expenses: $54.5 million, including $15 million related to acquisition and integration costs.
• Adjusted EBITDA: Loss of $11.9 million, compared to a loss of $5.5 million in Q3 2024.
• Cash Position: Ended the quarter with $138 million in cash and equivalents; expects to finish the year with approximately $120 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Successful integration of Akoya, achieving $67 million of the targeted $85 million in synergies within three months post-acquisition.
• Continued investment in R&D, totaling $27 million year-to-date (approximately 30% of revenue), focusing on Alzheimer's diagnostics and new assays.
• Early commercial momentum observed from combining Simoa and Spatial technologies, with cross-selling opportunities emerging in oncology and neurology.
• Launch of an early access program for Simoa One, aimed at gathering feedback ahead of a broader launch.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Expected to be between $130 million and $135 million, with Simoa revenue projected at $100 million to $105 million.
• Gross Margin Guidance: GAAP gross margin expected between 45% and 47%.
• Adjusted Cash Usage: Anticipated to be between $34 million and $38 million for the full year.
• 2026 Outlook: Cash flow breakeven expected, with continued investment in growth initiatives.

4. Bad News, Challenges, or Points of Concern

• Organic Revenue Decline: Simoa's consumable revenue declined significantly due to smaller project sizes in the academic sector, attributed to a challenging grant environment.
• Market Uncertainty: Ongoing government shutdown and uneven demand across academic and pharmaceutical markets create uncertainty for Q4 and beyond.
• Increased Operating Expenses: Sequential increase in operating expenses due to integration costs, raising concerns about profitability in the short term.
• Competitive Pressures: Emerging competition in high-sensitivity and multiplex platforms poses a challenge, particularly in the academic and discovery markets.

5. Notable Q&A Insights

• Consumable Revenue Decline: Management noted that while order volume remained stable, the size of orders decreased, impacting revenue. They expect project sizes to scale in 2026.
• Integration Progress: The integration of Akoya is ahead of schedule, with a unified leadership team and operational consolidation already in place.
• Diagnostics Revenue: The company anticipates stronger traction in diagnostics in 2026, supported by a positive pricing recommendation for the LucentAD test.
• Cross-Selling Opportunities: Early success in cross-selling between Simoa and Spatial products is being tracked, with positive initial feedback from customers.
• Government Shutdown Impact: The Q4 guidance reflects the potential impact of the government shutdown, with management expressing cautious optimism about a recovery if normalcy resumes.

Overall, Quanterix demonstrated resilience in a challenging environment, with strategic initiatives in place to drive future growth despite current headwinds.